NL-OMON39754已完成2 期
Mesenchymal stromal cells for treatment of drug resistant pediatric Juvenile idiopathic arthritis - MSC-JIA
niversitair Medisch Centrum Utrecht0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients (4-18 years of age) diagnosed with juvenile idiopathic arthritis according to the ILAR-criteria with active arthritis resistant to intra-articular steroids and systemic use of methotrexate and for whom no on-label indication exists for (not yet used) biologicals. The patient is followed for adverse events via the Pharmachild database. Signed informed consent by the patient and/or parent(s) or legal guardian(s)
排除标准
- •<4 or >18 years of age
- •Concurrent infection, febrile illness or malignancy.
- •Comedication: Biologic response modifiers.
- •Lack of written and verbal informed consent.
研究者
相似试验
已完成
不适用
Intraperitoneal infusion of ex vivo cultured allogeneic Natural Killer cells in recurrent ovarian carcinoma patients.Ovarian carcinoma10038594NL-OMON45699Radboud Universitair Medisch Centrum10
已完成
不适用
MEDIASTINAL STAGING OF NON SMALL CELL LUNG CANCER BY ENDOBRONCHIAL AND ENDOSCOPIC ULTRASONOGRAPHY WITH OR WITHOUT ADDITIONAL SURGICAL MEDIASTINOSCOPY (MEDIASTrial)lung cancernon-small cell lung cancerNL-OMON52981Maxima Medisch Centrum356
已完成
不适用
Clinical Application of a Dermal Substitute based on glycerol preserved Allograft: GLYADERM® A multicentre, prospective, controlled, randomized, comparative trial of Glyaderm® and split thickness skin graft versus split thickness skin graft alone in full thickness skin defectsburn woundsfull thickness skin defects1002211410040795NL-OMON36554Euro Tissue Bank2
已完成
3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): An Extension Study;(ROMANA-3)cachexiewasting syndroom1000301810027656NL-OMON38190Helsinn Therapeutics (U.S.), Inc1
已完成
3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-Ccachexiawasting syndroom1000301810027656NL-OMON37977Helsinn Therapeutics (U.S.), Inc2